These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

491 related items for PubMed ID: 18519520

  • 1. Development of hypogammaglobulinemia in patients treated with imatinib for chronic myeloid leukemia or gastrointestinal stromal tumor.
    Santachiara R, Maffei R, Martinelli S, Arcari A, Piacentini F, Trabacchi E, Alfieri P, Ferrari A, Leonardi G, Luppi G, Longo G, Vallisa D, Marasca R, Torelli G.
    Haematologica; 2008 Aug; 93(8):1252-5. PubMed ID: 18519520
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Elevations of creatine kinase in patients treated with imatinib mesylate (Gleevec).
    Gordon JK, Magid SK, Maki RG, Fleisher M, Berman E.
    Leuk Res; 2010 Jun; 34(6):827-9. PubMed ID: 19963273
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Acute myeloid leukemia developing during imatinib mesylate therapy for chronic myeloid leukemia in the absence of new cytogenetic abnormalities.
    Pawarode A, Sait SN, Nganga A, Coignet LJ, Barcos M, Baer MR.
    Leuk Res; 2007 Nov; 31(11):1589-92. PubMed ID: 17391756
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors.
    Demetri GD, von Mehren M, Blanke CD, Van den Abbeele AD, Eisenberg B, Roberts PJ, Heinrich MC, Tuveson DA, Singer S, Janicek M, Fletcher JA, Silverman SG, Silberman SL, Capdeville R, Kiese B, Peng B, Dimitrijevic S, Druker BJ, Corless C, Fletcher CD, Joensuu H.
    N Engl J Med; 2002 Aug 15; 347(7):472-80. PubMed ID: 12181401
    [Abstract] [Full Text] [Related]

  • 8. Imatinib mesylate (Glivec, Gleevec) in the treatment of chronic myelogenous leukemia (CML) and gastrointestinal stromal tumors (GIST).
    Hochhaus A.
    Ann Hematol; 2004 Aug 15; 83 Suppl 1():S65-6. PubMed ID: 15124676
    [No Abstract] [Full Text] [Related]

  • 9. Ocular side effects in chronic myeloid leukemia patients treated with imatinib.
    Breccia M, Gentilini F, Cannella L, Latagliata R, Carmosino I, Frustaci A, Alimena G.
    Leuk Res; 2008 Jul 15; 32(7):1022-5. PubMed ID: 18061664
    [Abstract] [Full Text] [Related]

  • 10. The safety profile of imatinib in CML and GIST: long-term considerations.
    Thanopoulou E, Judson I.
    Arch Toxicol; 2012 Jan 15; 86(1):1-12. PubMed ID: 21717109
    [Abstract] [Full Text] [Related]

  • 11. Imatinib-related bone marrow aplasia after complete cytogenetic response in chronic myeloid leukemia.
    Khan KA, Junaid A, Siddiqui NS, Mukhtar K, Siddiqui S.
    J Coll Physicians Surg Pak; 2008 Mar 15; 18(3):176-8. PubMed ID: 18460249
    [Abstract] [Full Text] [Related]

  • 12. Results of imatinib mesylate therapy in patients with refractory or recurrent acute myeloid leukemia, high-risk myelodysplastic syndrome, and myeloproliferative disorders.
    Cortes J, Giles F, O'Brien S, Thomas D, Albitar M, Rios MB, Talpaz M, Garcia-Manero G, Faderl S, Letvak L, Salvado A, Kantarjian H.
    Cancer; 2003 Jun 01; 97(11):2760-6. PubMed ID: 12767088
    [Abstract] [Full Text] [Related]

  • 13. The role of therapeutic drug monitoring of imatinib in patients with chronic myeloid leukemia and metastatic or unresectable gastrointestinal stromal tumors.
    Teng JF, Mabasa VH, Ensom MH.
    Ther Drug Monit; 2012 Feb 01; 34(1):85-97. PubMed ID: 22215488
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Oral pigmentation in the hard palate associated with imatinib mesylate therapy: a report of three cases.
    Mattsson U, Halbritter S, Mörner Serikoff E, Christerson L, Warfvinge G.
    Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2011 May 01; 111(5):e12-6. PubMed ID: 21330162
    [Abstract] [Full Text] [Related]

  • 16. Are there new clinical parameters useful to predict response in chronic myeloid leukemia in the imatinib era?
    Breccia M, Alimena G.
    Leuk Res; 2009 Nov 01; 33(11):1450-1. PubMed ID: 19615745
    [No Abstract] [Full Text] [Related]

  • 17. Population pharmacokinetics of imatinib mesylate and its metabolite in children and young adults.
    Menon-Andersen D, Mondick JT, Jayaraman B, Thompson PA, Blaney SM, Bernstein M, Bond M, Champagne M, Fossler MJ, Barrett JS.
    Cancer Chemother Pharmacol; 2009 Jan 01; 63(2):229-38. PubMed ID: 18398615
    [Abstract] [Full Text] [Related]

  • 18. [Imatinib mesylate in the treatment of advanced gastrointestinal stromal tumors].
    Wan DS, Wu XJ, Pan ZZ, Zhou ZW, Chen G, Li LR, Lu ZH, Ding PR.
    Zhonghua Yi Xue Za Zhi; 2006 Nov 21; 86(43):3064-7. PubMed ID: 17288838
    [Abstract] [Full Text] [Related]

  • 19. [Imatinib mesylate alone for refractory advanced gastrointestinal stromal tumor].
    Shen L, Jin ML.
    Zhonghua Zhong Liu Za Zhi; 2004 Nov 21; 26(11):697-9. PubMed ID: 15777512
    [Abstract] [Full Text] [Related]

  • 20. Development of multiple myeloma in a patient with chronic myeloid leukemia after treatment with imatinib mesylate.
    Garipidou V, Vakalopoulou S, Tziomalos K.
    Oncologist; 2005 Nov 21; 10(6):457-8. PubMed ID: 15967839
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 25.